Literature DB >> 6743769

The metabolism of cinnamic acid by healthy and phenylketonuric adults: a kinetic study.

J A Hoskins, S B Holliday, A M Greenway.   

Abstract

The enzyme phenylalanine ammonia lyase taken orally has been found to reduce the rise in blood phenylalanine that normally occurs following a protein meal. Therefore the enzyme has a potential use in the management of the genetic disease phenylketonuria. The enzyme mediates the conversion of phenylalanine to cinnamic acid and its possible clinical future has necessitated a more detailed study of the product of its reaction. Cinnamic acid is a compound of low toxicity which is converted in the mammalian body primarily to hippuric acid. We have examined the kinetics of this process in a healthy male and in two patients with untreated phenylketonuria. In addition we have attempted to clarify the inconsistencies in earlier published work about the status of other, minor metabolites. Following an oral load of sodium (2H6) cinnamate there is an increase in urinary hippuric acid largely due to the excretion of (2H5) hippuric acid. In the subjects studied there was no major difference in the rate of elimination although the amount of cinnamic acid converted was less in those with phenylketonuria. This may reflect reduced first-pass absorption by the liver in untreated phenylketonuria enabling increased uptake to occur in other parts of the body.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6743769     DOI: 10.1002/bms.1200110609

Source DB:  PubMed          Journal:  Biomed Mass Spectrom        ISSN: 0306-042X


  11 in total

1.  A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase.

Authors:  C N Sarkissian; Z Shao; F Blain; R Peevers; H Su; R Heft; T M Chang; C R Scriver
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

Review 2.  Up to date knowledge on different treatment strategies for phenylketonuria.

Authors:  Amaya Bélanger-Quintana; Alberto Burlina; Cary O Harding; Ania C Muntau
Journal:  Mol Genet Metab       Date:  2011-08-16       Impact factor: 4.797

3.  Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria.

Authors:  Christineh N Sarkissian; Tse Siang Kang; Alejandra Gámez; Charles R Scriver; Raymond C Stevens
Journal:  Mol Genet Metab       Date:  2011-06-29       Impact factor: 4.797

4.  Serum biomarkers of habitual coffee consumption may provide insight into the mechanism underlying the association between coffee consumption and colorectal cancer.

Authors:  Kristin A Guertin; Erikka Loftfield; Simina M Boca; Joshua N Sampson; Steven C Moore; Qian Xiao; Wen-Yi Huang; Xiaoqin Xiong; Neal D Freedman; Amanda J Cross; Rashmi Sinha
Journal:  Am J Clin Nutr       Date:  2015-03-11       Impact factor: 7.045

Review 5.  What we know that could influence future treatment of phenylketonuria.

Authors:  C N Sarkissian; A Gámez; C R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-08-03       Impact factor: 4.982

6.  Tubular Secretion in CKD.

Authors:  Astrid M Suchy-Dicey; Thomas Laha; Andrew Hoofnagle; Rick Newitt; Tammy L Sirich; Timothy W Meyer; Ken E Thummel; N David Yanez; Jonathan Himmelfarb; Noel S Weiss; Bryan R Kestenbaum
Journal:  J Am Soc Nephrol       Date:  2015-11-27       Impact factor: 10.121

7.  Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria.

Authors:  Christineh N Sarkissian; Alejandra Gámez; Lin Wang; Marilyse Charbonneau; Paul Fitzpatrick; Jeffrey F Lemontt; Bin Zhao; Michael Vellard; Sean M Bell; Carroll Henschell; Amy Lambert; Laurie Tsuruda; Raymond C Stevens; Charles R Scriver
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-18       Impact factor: 11.205

Review 8.  Phenylketonuria: translating research into novel therapies.

Authors:  Gladys Ho; John Christodoulou
Journal:  Transl Pediatr       Date:  2014-04

Review 9.  Phenylketonuria: a review of current and future treatments.

Authors:  Naz Al Hafid; John Christodoulou
Journal:  Transl Pediatr       Date:  2015-10

10.  First 1.5 years of pegvaliase clinic: Experiences and outcomes.

Authors:  Stephanie Sacharow; Cassandra Papaleo; Kyla Almeida; Benjamin Goodlett; Amy Kritzer; Harvey Levy; Leslie Martell; Ann Wessel; Krista Viau
Journal:  Mol Genet Metab Rep       Date:  2020-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.